MedWatch

New biotech firm wants to challenge vaccine giant: "Our product is better and cheaper"

Danish-Swedish biotech company 2A Pharma has taken the company's HPV vaccine into clinical development in record time. If everything goes well, the vaccine will enter a billion-dollar market in five years. "We have the potential to become quite big," says CEO.

Preben Bruun-Nyzell (left) and John Nieland, founders of 2A Pharma.

Things are moving fast for the young biotech company 2A Pharma that was founded in the end of 2016.

Just a few years after its establishment, the company has initiated phase I in-human trials with its lead candidate, the HPV vaccine 2AP01.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier